METHODS AND COMPOSITIONS FOR ENHANCING VACCINE IMMUNE RESPONSES
2 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a CD40 ligand (CD40L) and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increases T-cell immune responses specific for the heterologous disease-associated antigen when administered to a human host, and related methods and uses.
12 Citations
65 Claims
-
1-44. -44. (canceled)
-
45. A method of enhancing T-cell responses specific for a disease-associated antigen in a human comprising administering to the human a recombinant poxvirus comprising:
- (a) a nucleic acid sequence encoding a CD40 ligand (CD40L) and (b) a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the administration of the recombinant poxvirus induces increased T-cell immune responses specific for the heterologous disease-associated antigen, as compared to T-cell immune responses specific for the heterologous-disease associated antigen induced by a recombinant poxvirus comprising a heterologous disease associated antigen but not a CD40 antigen.
- View Dependent Claims (46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)
-
57. An immunogenic composition comprising a recombinant poxvirus, the poxvirus comprising:
- (a) a nucleic acid sequence encoding a CD40 ligand (CD40L) and (b) a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell immune responses specific for the heterologous disease-associated antigen when administered to a human host, as compared to T-cell immune responses specific for the heterologous-disease associated antigen induced by a recombinant poxvirus comprising a heterologous disease associated antigen but not a CD40 antigen.
- View Dependent Claims (58, 59, 60, 61, 62, 63, 64, 65)
Specification